1Kirpiehnikov D, McFarlane S I, Sowers J R. Metformin: an update[J]. Ann Intern Med,2002,137:25-33.
2Howlett H C,Bailey C J. A risk-benefit assessment of metformin in type 2 diabetes mellitus[J]. Drug Saf, 1999,20:489-503.
3UK Prospective Diabetes Study(UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes(UKPDS 34)[J]. Lancet, 1998,352:854-865.
4Tsur A, Harman-Bohem I, Buehs A E, Raz I, Wainstein J. The guidelines for the diagnosis prevention and treatment of type 2 diabetes mellitus-2005[J]. Harefuah, 2006,145: 583-586,630.
5Wilcox G. Insulin and insulin resistance[J]. Clin Biochem Rev, 2005,26 : 19-39.
6Paes A H, Bakker A, Soe-Agnie C J. Impact of dosage frequency on patient compliance[J]. Diabetes Care, 1997,20:1512-1517.
7Timmins P, Donahue S, Meeker J, Marathe P. Steady-state pharmaeokinetics of a novel extended-release metformin formulation[J]. Clin Pharmacokinet, 2005,44 : 721-729.
8Li J,Jin Y,Wang T Y,Lu X W,Li Y H. Relative bioavailability and bioequivalence of metforphin hydrochloride extended-released and immediate-released tablets in healthy Chinese volunteers[J]. Eur J Drug Metab Pharmacokinet, 2007,32 : 21-28.
9Schwartz S L,Wu J F,Berner B. Metformin extended release for the treatment of type 2 diabetes mellitus[J]. Expert Opin Pharmacother, 2006,7 : 803-809.
10Schwartz S, Fonseca V, Berner B, Cramer M, Chiang Y K, Lewin A. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes[J]. Diabetes Care, 2006,29 : 759-764.
